Combination of inhaled glucocorticosteroid with long-acting β2-agonist in asthma therapy in light of GINA 2024 recommendations Review article
Article Sidebar
Main Article Content
Abstract
The article was prepared for allergists, pulmonologists, pediatricians, family doctors and other specialists taking care of patients with asthma. The aim of the paper is to summarize the current guidelines for the treatment of asthma in adults and adolescents over 12 years of age in a simple and transparent manner. Two therapeutic paths proposed in the GINA 2024 recommendations are presented and when to choose each one is indicated. The focus is on the alternative path in the context of the combination of fluticasone propionate with salmeterol in a dry powder inhaler. The advantages of the above combination of a glucocorticosteroid with a long-acting β2-agonist over other therapies in terms of pharmacodynamic and pharmacokinetic properties, as well as clinical efficacy, are discussed.
Downloads
Article Details
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Reddel HK, FitzGeralnd JM, Bateman ED et al. GINA 2019: a fundamental change in asthma management. ERJ 2019; 53(6): 1901046.
3. Numbere B, Liu Y, Zhang S et al. Characteristics, treatment patterns and burden of illness in US patients with asthma newly initiating multiple-inhaler triple therapy. BMJ Open Respir Res. 2024; 11(1): e001702.
4. Charakterystyka produktu leczniczego Aurodisc.
5. Charakterystyka produktu leczniczego Symbicort Turbuhaler.
6. Charakterystyka produktu leczniczego Fostex NEXThaler.
7. Charakterystyka produktu leczniczego Relvar Ellipta.
8. Charakterystyka produktu leczniczego Atectura Breezhaler.
9. Charakterystyka produktu leczniczego Seretide.
10. Charakterystyka produktu leczniczego Fostex.
11. Matera MG, Rinaldi B, Calzetta L et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. Pulm Pharmacol Ther. 2019; 58: 101828.
12. Velayati A, Hosseini SA, Sari AA et al. Comparison of the effectiveness and safety of formoterol versus salmeterol in the treatment of patients with asthma: A systematic review and meta-analysis. J Res Med Sci. 2015; 20(5): 483-90.
13. Rogliani P, Calzetta L, Braido F et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018; 13: 3115-30.
14. Lasserson TJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev. 2011; (12): CD004106.
15. Singh D, Garcia G, Maneechotesuwan K et al. New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management. Adv Ther. 2022; 39(5): 1895-914.
16. Singh D, Oosterholt S, Pavord I et al. Understanding the clinical implications of individual patient characteristics and treatment choice on the risk of exacerbation in asthma patients with moderate-severe symptoms. Adv Ther. 2023; 40(10): 4606-25.
17. Kuna P. Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, doubl-blind study. Clin Drug Investig. 2010; 30(9): 565-79.
18. Tashkin DP, Koltun A, Wallace R. A generic fluticasone propionate and salmeterol dry powder inhaler: evidence of usability, function, and robustness. Allergy Asthma Proc. 2021; 42(1): 30-5.
19. Janeczek K, Emeryk A. Porównanie preparatów propionianu flutykazonu z salmeterolem dostępnych w inhalatorach dyskopodobnych oraz Dysku (doniesienie wstępne). Terapia. 2022; 8(415): 20-8.
20. Sheth K, Bernstein JA, Lincourt WR et al. Patient perceptions of an inhaled asthma medication administered as an inhalation powder via the Diskus or as an inhalation aerosol via a metered-dose inhaler. Ann Allergy Asthma Immunol. 2003; 91: 55-60.
21. Emeryk A, Emeryk-Maksymiuk J, Janeczek K et al. Inhalatory suchego proszku w dobie pandemii COVID-19 – co jest ważne dla pacjenta ? Alergoprofil. 2021; 17(2): 3-9.
22. Polski Przewodnik Inhalacyjny. Wydanie II. Emeryk A, Pirożyński M, Mazurek H (eds). Via Medica, Gdańsk 2021.
23. Pawliczak R, Emeryk A, Kupczyk M et al. Standardy rozpoznawania i leczenia astmy Polskiego Towarzystwa Alergologicznego, Polskiego Towarzystwa Chorób Płuc i Polskiego Towarzystwa Medycyny Rodzinnej (STAN3T). Alergologia Polska – Polish Journal of Allergology. 2023; 10: 1-14.
24. Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019; 15: 461-72.
25. Emeryk A, Pirożyński M, Emeryk-Maksymiuk J. Dry powder inhalers – between the doctor and the patient. Adv Respir Med. 2018; 86(1): 44-52.
26. Ansari SF, Memon M, Kumar R et al. Risk Factors Associated With Frequent Acute Exacerbations of Asthma. Cureus. 2020; 12(10): e11090.
27. Wang L, Zhou L, Zheng P et al. Mild asthma is not mild: risk factors and predictive biomarkers for severe acute exacerbations and progression in mild asthma. Expert Rev Respir Med. 2023; 17(12): 1261-71.